These results demonstrated that CYLD expression levels were decreased in ovarian cancer patients as they gained resistance to DDP treatment, suggesting that CYLD is a DDP sensitizer and new biomarker of ovarian cancer DDP resistance. Here, CYLD is linked to ovarian carcinoma.